Potential Novel Thioether-Amide or Guanidine-Linker Class of SARS-CoV-2 Virus RNA-Dependent RNA Polymerase Inhibitors Identified by High-Throughput Virtual Screening Coupled to Free-Energy Calculations.
Marko JukičDušanka JanežičUrban BrenPublished in: International journal of molecular sciences (2021)
SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2, represents a new pathogen from the family of Coronaviridae that caused a global pandemic of COVID-19 disease. In the absence of effective antiviral drugs, research of novel therapeutic targets such as SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) becomes essential. This viral protein is without a human counterpart and thus represents a unique prospective drug target. However, in vitro biological evaluation testing on RdRp remains difficult and is not widely available. Therefore, we prepared a database of commercial small-molecule compounds and performed an in silico high-throughput virtual screening on the active site of the SARS-CoV-2 RdRp using ensemble docking. We identified a novel thioether-amide or guanidine-linker class of potential RdRp inhibitors and calculated favorable binding free energies of representative hits by molecular dynamics simulations coupled with Linear Interaction Energy calculations. This innovative procedure maximized the respective phase-space sampling and yielded non-covalent inhibitors representing small optimizable molecules that are synthetically readily accessible, commercially available as well as suitable for further biological evaluation and mode of action studies.
Keyphrases
- sars cov
- molecular dynamics simulations
- respiratory syndrome coronavirus
- high throughput
- molecular docking
- small molecule
- density functional theory
- molecular dynamics
- protein protein
- endothelial cells
- coronavirus disease
- adverse drug
- binding protein
- emergency department
- climate change
- amino acid
- transcription factor
- machine learning
- nucleic acid
- dna binding
- neural network
- pluripotent stem cells
- induced pluripotent stem cells
- case control